NCT00003239View on ClinicalTrials.gov

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 1998

Primary Completion Date

October 31, 2001

Study Completion Date

October 31, 2001

Conditions
Leukemia
Interventions
BIOLOGICAL

Recombinant Interferon Alfa

Daily by subcutaneous injection.

DRUG

Cytarabine

Daily by subcutaneous injection.

DRUG

Omacetaxine Mepesuccinate

Homoharringtonine is administered by continuous infusion on days 1-5.

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00003239 - Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter